Phase 1 N=14 Phase I Study of Pyrimethamine in Healthy Japanese and Caucasian Subjects
Toxoplasmosis
Primary: Maximum Observed Concentration (Cmax) of Pyrimethamine in Healthy Japanese Male Participants — 430.5 Nanogram per milliliter
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=72 Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction
Neoplasms · Lymphomas
Primary: Dose Limiting Toxicity (DLTs) — 0; 0; 0; 0 Toxicities
Phase 1 N=24 A Study of Baricitinib in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Baricitinib Following a Single Oral Dose — 49.8; 49.6; 47.8; 47.9 nanograms per milliliter (ng/mL)
Phase 1 N=80 To Investigate the Safety, Tolerability, Pharmacokinetics and the Relative Bioavailability of BI 1026706
Healthy
Primary: Number of Subjects With Drug Related Adverse Events — 0.0; 33.3; 16.7; 16.7 Percentage of participants
Phase 1 N=58 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1026706 in Male and Female Healthy Subjects and Patients With Osteoarthritis of the Knee
Osteoarthritis
Primary: Percentage of Subjects With Drug Related Adverse Events — 22.2; 22.2; 11.1; 66.7 Percentage of participants
Phase 1 N=15 A Drug Interaction Study of Lanabecestat (LY3314814) and Warfarin in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Unbound S-Warfarin — 3.50; 3.73 nanogram per milliliter (ng/mL)
Phase 1 N=55 Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib
Solid Tumors · Lymphoma
Primary: Cmax: Maximum Observed Concentration for Alisertib in Presence and Absence of Esomeprazole — 1542.6; 1804.8 nmol/L
Phase 1 N=19 Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours
Advanced Solid Tumours
Primary: Number of Patients With Treatment-Emergent Adverse Events — 7; 6; 6; 6 Participants
Phase 1 N=18 A Study of Lanabecestat (LY3314814) in Healthy Participants
Healthy
Primary: Pharmacokinetics(PK): Maximum Concentration (Cmax) of LY3314814 (AZD3293) — 194; 212; 164; 208 nanogram per milliliter (ng/mL)
Phase 1 N=28 Bioequivalence Study Between SKF101804 Cefixime 200 Milligram (mg)/5 Milliliter (mL) Suspension Versus Cefixime 200 mg/5 mL Suspension Reference Product in Healthy Adult Subjects Under Fasting Conditions
Infections, Bacterial
Primary: Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration Within a Participant Across All Treatments (AUC [0-t]) for…
Phase 1 N=82 A Drug-Drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants
Healthy
Primary: Pharmacokinetic (PK): Area Under the Curve Zero to Infinity (AUC[0-∞]) for LY3314814 — 3200 Nanogram * hour per milliliter (ng*h/mL)
Phase 1 N=8 A Study of LY3314814 in Healthy Participants
Healthy
Primary: Absolute Bioavailability of LY3314814 — 60.5; 59.2 nanogram*hour per milliliter per mg
Phase 1 N=103 Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151)
Melanoma
Primary: Number of Participants Who Experienced At Least One Adverse Event (AE) — 101 Participants
Phase 1 N=96 A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects
Healthy Male Subjects · Cardiovascular Disease
Primary: Safety and Tolerability of AZD5718 by Assessment of the Number of Participants With Adverse Events Following Oral Administration of SAD (Part A) and MAD (Part B). — 15…
Phase 1 N=7 A Study of LY3113593 in Participants With Chronic Kidney Disease
Chronic Kidney Disease
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 1 Participants